Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $385.4652W HIGH $643.99
Volume
1.58 M
Value Traded
1.11 B
Short % Float
1.36%
+0.96%Week
-14.88%1 Month
-12.22%3 Month
-21.77%6 Month
-4.13%5 Year
+35,528.45%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
243.30 B
EPS (TTM)
18.21
P/E Ratio
24.65
Ent. Value
206.62 B
Total Shares
369.82 M
Float Shares
368.77 M
Insiders
0.26%
Institutions
94.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TMO Catalyst Timeline
Dated clinical, regulatory and corporate events for Thermo Fisher Scientific Inc
Past FDA Catalysts and PDUFA Decisions
How TMO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Thermo Fisher Scientific Inc is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TMO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pettiti GianlucaOfficer (President & COO) | Sell | -400 23,216.14 held | $614.38 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TMO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.8 % (60 %) | 45.47 M | 90.70 K | 95.05% ( 44.20 K) |
TMO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TMO ranks across every disease it competes in
Competitive Position is a premium feature
See how TMO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTMO News
TMOThermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026
Thermo Fisher Scientific is set to showcase its expanded drug development and manufacturing capabilities at CPHI Milan 2026. The company aims to assist pharmaceutical and biotechnology firms in navigating complex commercialization processes. Among its new offerings is OSD Express, designed to enhance predictability in drug development.
Read more →TMOThermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study
Thermo Fisher Scientific has announced a successful collaboration with Precision Health Research and Nanyang Technological University, resulting in the identification of more than 2,500 new genetic-protein associations. This achievement leverages Thermo Fisher's advanced proteomics technologies alongside extensive health and genomic data from the PRECISE-SG100K study. The findings are expected to significantly advance biological research.
Read more →TMOThermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
Thermo Fisher Scientific Inc. will announce its financial results for Q3 2026 before the market opens on October 21, 2026. A conference call is scheduled for the same day at 7:00 a.m. ET, where the company will discuss its financial performance and future expectations. The call will be available via live webcast.
Read more →TMOThermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
Evosep has entered a reseller agreement with Thermo Fisher Scientific to offer the Evosep Eno separation platform. This partnership aims to enhance access to standardized proteomics workflows, combining Thermo Fisher's mass spectrometry expertise with Evosep's innovative technology. The Evosep Eno platform is designed for high throughput and reproducibility in research and clinical applications.
Read more →TMOThermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
Thermo Fisher Scientific has launched the Gibco™ CHO-K1 Catalog Panel, a cGMP-ready media portfolio aimed at enhancing biologics development. This new offering includes various basal and feed media options that support robust cell growth and protein production in CHO-K1 cell lines. The panel is available in both liquid and dry powder formats, providing flexibility for process development and scaling.
Read more →TMOThirty Inspiring Middle School Scientists and Engineers Named Finalists in the 2026 Thermo Fisher Scientific Junior Innovators Challenge
The Society for Science has announced the 30 finalists for the 2026 Thermo Fisher Scientific Junior Innovators Challenge, showcasing young talent from 17 U.S. states and Puerto Rico. These finalists will compete in Washington, D.C. for over $100,000 in awards, including the prestigious $25,000 ASCEND Award. The competition emphasizes the importance of STEM education and aims to inspire future innovators.
Read more →TMOMayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear
Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC, a new initiative aimed at identifying early biological signals of disease. This partnership will generate a large biomedical dataset through multi-omics data integration, potentially accelerating drug development and enabling earlier diagnosis and personalized care. The collaboration leverages advanced AI and extensive clinical data to enhance understanding of disease progression.
Read more →TMOThermo Fisher Scientific Announces Quarterly Dividend - May 20, 2026
Thermo Fisher Scientific has announced a quarterly cash dividend of $0.47 per share, which will be paid on July 15, 2026. Shareholders of record as of June 15, 2026, will be eligible for this dividend. The announcement underscores the company's strong financial position and commitment to returning value to its shareholders.
Read more →TMOThermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
Thermo Fisher Scientific has signed an agreement to sell its microbiology business to Astorg for approximately $1.075 billion. This business, which generated $645 million in revenue in 2025, is part of Thermo Fisher's Specialty Diagnostics segment. The transaction is expected to close in the second half of 2026, subject to regulatory approvals. It is anticipated to have a dilutive effect on earnings in the first year post-closure.
Read more →TMO▼ -9.2%on this newsshared move
Thermo Fisher Scientific Reports First Quarter 2026 Results
Thermo Fisher Scientific reported a strong financial performance for the first quarter of 2026, with revenues increasing by 6% to $11.01 billion and GAAP diluted EPS rising by 11% to $4.43. The company launched several innovative products and formed strategic collaborations with NVIDIA and SHL Medical to enhance its capabilities. However, organic revenue growth was modest at 1%, and there was a slight decrease in GAAP operating margin compared to the previous year.
Read more →TMOThermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
Thermo Fisher Scientific has announced a strategic collaboration with Precision Health Research, Singapore, to enhance the PRECISE-SG100K study, a significant population-scale biobank initiative. This partnership aims to leverage proteomics and AI-driven analytics to improve disease detection and personalized care. The study will integrate advanced technologies to analyze a diverse cohort, contributing to precision medicine.
Read more →TMOThermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.
Thermo Fisher Scientific has completed the acquisition of Clario Holdings, Inc. This strategic move is expected to enhance Thermo Fisher's capabilities in the biopharma sector. The acquisition aligns with Thermo Fisher's growth strategy, although specific details on the impact remain undisclosed.
Read more →TMOThermo Fisher Scientific Increases Quarterly Dividend
Thermo Fisher Scientific Inc. has announced a 10% increase in its quarterly cash dividend, raising it to $0.47 per share. This dividend will be payable on April 15, 2026, to shareholders of record as of March 13, 2026. The increase reflects the company's ongoing commitment to delivering value to its shareholders.
Read more →TMOThermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference
Thermo Fisher Scientific Inc. will have its CEO, Marc N. Casper, present at the Raymond James Institutional Investors Conference on March 3, 2026. The presentation will be available via a live webcast, with a replay accessible shortly after. The company continues to emphasize its mission to support advancements in life sciences and diagnostics.
Read more →TMOThermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
Thermo Fisher Scientific reported strong financial results for Q4 and full year 2025, with revenues increasing by 7% and 4% respectively. The company highlighted its effective growth strategy and operational performance, resulting in higher earnings per share. Looking ahead, Thermo Fisher is optimistic about its position entering 2026, anticipating continued growth and value creation for stakeholders.
Read more →TMOThermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026
Thermo Fisher Scientific Inc. will announce its financial results for Q4 and the full year 2025 on January 29, 2026. The company will hold a conference call at 8:30 a.m. ET to discuss its performance and future expectations. The call will be available via live webcast and will include a replay option.
Read more →TMONovo Nordisk Taps Thermo Fisher to Help Meet Wegovy Demand: Reuters
Novo Nordisk has enlisted Thermo Fisher Scientific to assist in manufacturing its weight-loss drug Wegovy, amid ongoing production issues with the initial manufacturer, Catalent. The decision comes as demand for Wegovy surges, following significant production delays attributed to Catalent's facilities. Despite these challenges, Catalent's shares saw a rise after reporting better-than-expected earnings.
Read more →TMOUltragenyx Sued by Henrietta Lacks’ Family in Second HeLa Cell Line Lawsuit
The family of Henrietta Lacks has filed a lawsuit against Ultragenyx Pharmaceutical, alleging the company used her HeLa cells without consent for commercial gain. The lawsuit accuses Ultragenyx of unjust enrichment and seeks to prevent further use of the cells. This legal action follows a recent settlement with Thermo Fisher Scientific over similar claims, emphasizing ongoing concerns about racial injustice in medical research.
Read more →About Thermo Fisher Scientific Inc
Headquarters168 THIRD AVENUE, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE PLUS
Trade the next TMO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime